Robuta

https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28936912/analysts-put-alnylam-on-upside-catalyst-watch-ahead-of-upcoming-data-from-lead-prog
analystsputalnylamupsidecatalyst
https://www.greatplacetowork.co.uk/certified-company/1535623
Discover why Alnylam is Great Place To Work Certified. Explore their workplace culture and find out what employees say about what it's like to work at Alnylam.
workingalnylamgreatplaceuk
https://www.roche.com/investors/updates/inv-update-2025-08-30
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the Phase II KARDIA-3...
phase iiirochealnylamadvancezilebesiran
https://www.alnylam.com/patients/patient-services
Learn more about the patient services Alnylam offers, including Alnylam Assist® and Alnylam Act™.
alnylamamppatientservicespharmaceuticals
https://www.benzinga.com/markets/large-cap/25/11/49119950/whats-going-on-with-alnylam-stock-on-friday
Alnylam stock climbs as earnings beat, sales soar and new Amvuttra data shows cardiac benefits, adding momentum to its strong 2025 run.
going onalnylamstockfriday
https://www.greatplacetowork.co.uk/resources/3-ways-alnylam-fosters-a-sense-of-pride-in-the-workplace
Discover how Alnylam fosters pride in its employees through patient-centricity, corporate social responsibility, and employee recognition.
in thewaysalnylamfosterssense
https://www.alnylam20th.com/
Celebrating 20 Years of Alnylam Leadership in RNAi
homepagealnylamanniversary
https://alnylamevents.com/patientevents?id=EM-05546
patienteventsregistrationalnylam
https://www.biospace.com/genzyme-corporation-exercises-right-to-increase-stake-in-alnylam-pharmaceuticals
genzyme corporationalnylam pharmaceuticalsexercisesrightincrease
https://www.greaterzuricharea.com/en/success-stories/alnylam
Alnylam is the biotech industry pioneer leading the translation of RNA interference (RNAi) and has its European headquarters in Greater Zurich.
greater zurichalnylam
https://www.biopharmadive.com/news/fdas-rapid-review-pace-nets-an-early-approval-for-alnylams-second-drug/567754/
Givosiran, which will be sold as Givlaari, is the second RNAi therapeutic cleared by the agency after Alnylam's Onpattro.
fdarapidreviewpacenets
https://informaconnect.com/asia-tides/speakers/muthiah-mano-manoharan-phd/
Informa Connect's TIDES Asia is the only event in Asia bringing together science, technologies and partners to accelerate oligonucleotide and peptide molecules...
alnylam pharmaceuticalsmuthiahmanophdtides
https://www.biospace.com/alnylam-pharmaceuticals-initiates-phase-i-clinical-study-for-aln-ttrsc-a-subcutaneously-administered-rnai-therapeutic-targeting-transthyretin-ttr-f
alnylam pharmaceuticalsclinical studyinitiatesphase
https://www.porphyria.com/ahp-resources/patient-educators
Alnylam Patient Education Liaisons are experienced in educating people and their families about acute hepatic porphyria (AHP). Request to speak with an...
patient educationconnectalnylamliaisonpinpoint
https://www.alnylamconnect.eu/
Healthcare professionals only: Learn more about Alnylam's therapeutic areas by speaking with an Alnylam representative (by phone, email, video chat, or in...
therapeuticareasalnylamconnect
https://www.benzinga.com/insights/news/24/10/41499561/100-invested-in-alnylam-pharmaceuticals-15-years-ago-would-be-worth-this-much-today
alnylam pharmaceuticalsyears agoinvestedwould